Immunogenicity, Pathogenesis, and Host’s Immuno-Responses to Marburg Virus Infection
Pathogens,
Год журнала:
2025,
Номер
14(4), С. 323 - 323
Опубликована: Март 27, 2025
Due
to
the
sudden
emergence
and
burnout
nature
of
Marburg
virus
(MARV)
outbreaks,
little
is
known
about
MARV's
pathogenicity
immunogenicity.
These
gaps
in
knowledge
are
limiting
our
understanding
disease
implementation
cost-effective
prevention
control
measures
including
case
management
through
safe
effective
therapeutic
modalities.
Therefore,
this
review
aims
synthesize
summarize
evidence
pathogenicity,
immunogenicity,
virulence
humans
towards
MARV.
Upon
infection,
MARV
rapidly
disseminates
throughout
various
tissues,
provoking
severe
cellular
injury,
particularly
lymphatic
organs,
liver,
kidneys,
gastrointestinal
tract.
The
takes
advantage
host
cells
by
avoiding
immune
responses,
mainly
disrupting
function
dendritic
blocking
signaling
pathways
for
interferon.
As
a
result,
patients
experience
profound
dysregulation
characterized
early
lymphocyte
depletion
shift
pro-inflammatory
cytokine
release,
resulting
storm
that
can
lead
hemorrhagic
septic
shock.
Additionally,
adaptive
antibody
production,
impaired,
further
complicating
recovery
increasing
susceptibility
outcomes.
Understanding
these
intricate
host-pathogen
interactions
critical
developing
strategies
vaccines
against
Continuing
research
essential
explain
mechanisms
evasion
identify
potential
intervention
points
improving
patient
Язык: Английский
Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease
Pathogens,
Год журнала:
2025,
Номер
14(4), С. 322 - 322
Опубликована: Март 27, 2025
During
the
current
outbreak
of
Marburg
virus
disease
(MVD)
in
Rwanda,
we
synthesized
evidence
from
literature
to
improve
case
management.
Accordingly,
experimental
treatment
was
offered
patients
under
close
follow-up.
Remdesivir
alone
or
combination
with
monoclonal
antibody
(MBP091)
complemented
supportive
care
has
improved
clinical
outcomes
patients.
Additionally,
have
identified
several
therapies
currently
investigation,
including
antiviral
drugs
such
as
favipiravir,
galidesivir,
obeldesivir,
and
remdesivir,
along
polyclonal
antibodies
(e.g.,
IgG,
MR-78-N;
MR82-N;
MR191-N;
MR186-YTE
MBP091).
Furthermore,
substantial
progress
is
being
made
vaccine
development,
promising
candidates
adenovirus-vectored
vaccines,
DNA
recombinant
vesicular
stomatitis
(rVSV)
vaccine.
Moreover,
innovative
preventive
strategies-such
synthetic
hormones
like
estradiol
benzoate,
small
interfering
RNA
(siRNA),
interferon-β
therapy,
phosphorodiamidate
morpholino
oligomers-are
emerging
potential
options
for
MVD
Further
investment
needed
accelerate
research
optimize
these
therapeutics
modalities.
Additional
epidemiological,
preclinical,
studies
are
warranted
generate
required
inform
policymaking,
resource
mobilization,
implementation
cost-effective
interventions
prevention,
control,
MVD.
Язык: Английский